Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy

Springer Science and Business Media LLC - Tập 19 - Trang 1-7 - 2019
Erina Goda1, Kazuyuki Hirooka1,2, Kazuhiko Mori3, Yoshiaki Kiuchi2
1Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan
2Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
3Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan

Tóm tắt

To examine the use of ripasudil as a trabeculotomy outcome marker in patients with primary open-angle glaucoma (POAG). Between May 2015 and December 2018, 35 eyes underwent trabeculotomy and were postoperatively followed for over 3 months. Ripasudil was defined as effective if drug administration resulted in a greater than 10% reduction in intraocular pressure (IOP). Patients were divided into effective (effective group) or non-effective (non-effective group) ripasudil administration groups. The need for additional glaucoma surgery or an IOP ≥ 21 mmHg indicated surgical failure. In both groups, a Kaplan-Meier survival-analysis was used to evaluate success probabilities related to postoperative IOP levels. Effective IOP reduction occurred in 14 of 35 eyes after ripasudil administration, which was shown by a decrease of more than 10%. Postoperatively, both groups exhibited significant reductions of IOP and antiglaucoma medication use for up to 24 months. At 12 and 24 months after trabeculotomy, probabilities of success in the effective vs. non-effective group were 100% vs. 94.7 and 100% vs. 75.4%, respectively (P = 0.14). Trabeculotomy is effective for achieving an IOP < 21 mmHg in ripasudil effective POAG eyes. Examination of ripasudil’s IOP-lowering effects may be useful in predicting surgical outcomes after trabeculotomy.

Tài liệu tham khảo

Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, Narumiya S, Honda Y. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137–44. Tokushige H, Inatani M, Nemoto S, Sakaki H, Katayama K, Uehata M, Tanihara H. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216–22. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. K-115 Clinical Study Group. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731–6. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, Araie M. K-115 clinical study group. Intra-ocular pressure-lowering effects of a rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254–60. Sato S, Hirooka K, Nitta E, Ukegawa K, Tsujikawa A. Additive intraocular pressure lowering effects of the rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33:1628–34. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42:1029–37. Tanihara H, Negi A, Akimoto M, Terauchi H, Okudaira A, Kozaki J, Takeuchi A, Nagata M. Surgical effects of trabeculotomy ab externo on adult eyes with primary open angle glaucoma and pseudoexfoliation sysndrome. Arch Ophthalmol. 1993;111:1653–61. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, Araie M. K-115 clinical study group. Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trial. JAMA Ophthalmol. 2015;133:755–61. Dannheim R. Symposium: microsurgery of the outflow channels. Trabeculotomy Trans Am Acad Ophthalmol Otolaryngol. 1972;76:375–83. Iwao K, Inatani M, Tanihara H, Japanese Steroid-induced Glaucoma Multicenter Study Group. Success rate of trabeculotomy for steroid-induced glaucoma: a comparative, multicenter, retrospective cohort study. Am J Ophthalmol. 2011;151:1047–56. Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, Yamane S, Kadonosono K. Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. J Glaucoma. 2017;26:96–100. Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, Yamane S, Kadonosono K. One-year efficacy of adjunctive use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol. 2017;255:2009–15. Inoue K, Okayama R, Shiokawa M, Ishida K, Tomita G. Efficacy and safety of adding ripasudil to existing treatment regiments for reducing intraocular pressure. Int Ophthalmol. 2018;38:93–8. Tanihara H, Honjo M, Inatani M, Honda Y, Ogino N, Ueno S, Negi A, Ichioka H, Mizoguchi T, Matsumura M, Nagata M. Trabeculotomy combined with phacoemulsification and implantation of an intraocular lens for the treatment of primary open-angle glaucoma and coexisting cataract. Ophthalmic Surg Lasers. 1997;28:810–7. Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016;10:189–206. Fellman RL, Feuer WJ, Grover DS. Episcleral venous fluid wave correlated with trabectome outcomes: intraoperative evaluation of the trabecular outflow pathway. Ophthalmology. 2015;122:2385–91.